Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
15/09/2026 15:35
BRIEF-Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma Sept 15 (Reuters) - Aurobindo Pharma Limited ARBN.NS:
AUROBINDO PHARMA - US FDA INSPECTED API MANUFACTURING FACILITY OF UNIT APITORIA PHARMA
AUROBINDO PHARMA - INSPECTION CONCLUDED WITH ONE OBSERVATION, WHICH IS PROCEDURAL IN NATURE
Source text: ID:nnAZN4TK7R6
Further company coverage: ARBN.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11